The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 13 | — | 20.8x | Bottom tier | |
Growth | 72 | — | 6.1% | Top tier | |
Quality | 44 | -15.8% | 6.6% | Around median | |
Safety | 29 | 1.8x | 0.7x | Bottom tier | |
Capital Return | 86 | — | 2.02% | Top tier | |
Momentum | 82 | 51.1% | 4.1% | Top tier | |
Sentiment | 69 | 4 | 3 | Top tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Lexicon Pharmaceuticals, Inc. (LXRX) is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative, targeted oral therapies for patients with severe chronic diseases. The company primarily concentrates its operations on two key therapeutic areas: cardiometabolic diseases and chronic pain. The company generates its revenues from commercial sales of its approved product, INPEFA (sotagliflozin), for heart failure patients, alongside upfront payments and development and licensing milestones resulting from its strategic partnerships with global pharmaceutical companies such as Novo Nordisk and Viatris.
During the first quarter of 2026, the company achieved a strong leap in total revenues to reach $21.1 million, compared to $1.3 million in the same quarter of 2025. This exceptional growth is mainly attributed to recording two development milestone payments of $10 million each (totaling $20 million) under the licensing agreement for compound LX9851 with Novo Nordisk, in addition to achieving net sales of $1.1 million for INPEFA. As a result of strict financial discipline, the net loss narrowed significantly to just $1.0 million (or less than $0.01 per share) compared to a loss of $25.3 million in the first quarter of 2025, supported by a decline in research and development expenses to $12.8 million and selling and administrative expenses to $9.2 million.
The valuation of Lexicon Pharmaceuticals (LXRX) is currently aligned with the analyst consensus rating the stock as Hold, with an average target price of $6.00, with both the high and low estimates matching the same figure. The stock is currently trading significantly below this expected price target, reflecting market caution ahead of critical regulatory and clinical milestones for sotagliflozin and Zynquista in the second half of 2026. It is worth noting that the company's P/E ratio is currently unavailable due to ongoing operating losses, despite the substantial narrowing of the net loss in the recent quarter.
Figures in the text are as of 2026-06-15; the live price is shown at the top of the page.
The company achieved total revenues of $21.1 million in the first quarter of 2026, compared to $1.3 million in the first quarter of 2025. The licensing agreement with Novo Nordisk contributed $20 million as development milestone payments, while net sales of INPEFA reached $1.1 million. The company successfully narrowed its net loss significantly to $1.0 million, compared to a loss of $25.3 million in the prior year's comparative period. This financial improvement is attributed to operational discipline and a reduction in operating expenses by approximately $4.8 million.
The company continues to make rapid progress in the Phase 3 SONATA study evaluating sotagliflozin in approximately 500 patients with hypertrophic cardiomyopathy across 130 sites in 20 countries. The company expects to complete full patient enrollment by mid-2026 based on currently strong enrollment rates. Topline clinical data from this pivotal study is expected to be announced in the first quarter of 2027. This study aims to support broad regulatory filings for patients with both obstructive and non-obstructive symptoms.
Lexicon aims to resubmit the NDA for Zynquista to the U.S. FDA by mid-2026. This submission is based on clinical data from the STENO1 study led by independent investigators in Denmark. If regulatory processes proceed as planned, there is a strong opportunity to obtain approval and enter the market before the end of 2026. If approved, the drug will represent the first oral adjunct therapy to insulin for patients with type 1 diabetes.
Automated analysis for informational purposes only — not investment advice.
During the first quarter of 2026, the company announced a $100 million credit facility with Hercules Capital to enhance its financial flexibility. A first tranche of $55 million was drawn at closing and fully utilized to settle the outstanding loan with Oxford Finance. A second tranche of $20 million and a third tranche of $25 million are available and can be optionally drawn by Lexicon upon achieving specific clinical, regulatory, and financial milestones. This facility provides an initial interest-only period of 18 months, with the possibility of extension.
Lexicon has a licensing agreement with Novo Nordisk to develop compound LX9851, an innovative oral ACSL5 inhibitor for the treatment of obesity. In March 2026, Novo Nordisk launched a Phase 1 clinical study for this compound, reflecting its rapid commitment to its development. This clinical progress triggered a $10 million milestone payment to Lexicon, which is the second milestone achieved under this agreement during the first quarter. Novo Nordisk continues to prioritize the development of this promising asset within its obesity treatment portfolio.